Ads
related to: what is non-small cell lung cancer- New Treatment Option
Learn More About A Treatment For
Resectable NSCLC.
- Downloadable Resources
Find Support And Download A Patient
& Caregiver Guide On The Site.
- Discover The Data
See The New Trial Data. Visit
The Treatment Option Site.
- Financial Support Info
See The Financial Resources
For A New NSCLC Treatment.
- See A Dosing Guide
View Patient Dosing Information
For A New NSCLC Treatment.
- Talk To Your Doctor
It's Important To Talk With Your
Care Team About Your Treatment.
- New Treatment Option
Search results
Results From The WOW.Com Content Network
Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with programmed death receptor 1 (PD-1) expressed on the surface of T cells, and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody.
In addition to recognizing cancerous cells, a pathologist can classify the tumor according to the type of cells it originates from. Around 15% of cases are small-cell lung cancer (SCLC), and the remaining 85% (the non-small-cell lung cancers or NSCLC) are adenocarcinomas, squamous-cell carcinomas, and large-cell carcinomas.
Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). It is the second most prevalent type of lung cancer after lung adenocarcinoma and it originates in the bronchi. Its tumor cells are characterized by a squamous appearance, similar to the one observed in epidermal cells.
Non-small cell lung cancer is a common type of lung cancer that is often diagnosed with a physical exam, blood tests, imaging studies, procedures, and biopsies.
A Pancoast tumor is a tumor of the apex of the lung. It is a type of lung cancer defined primarily by its location situated at the top end of either the right or left lung. It typically spreads to nearby tissues such as the ribs and vertebrae. Most Pancoast tumors are non-small-cell lung cancers.
The approval allows the use of the cancer drug, Rybrevant, in combination with J&J's existing drug, lazertinib, as a first-line treatment for non-small cell lung cancer (NSCLC) patients with a ...
Ads
related to: what is non-small cell lung cancer